A Phase 3 interventional study of Nerandomilast and Placebo in Fibrosing Interstitial Lung Disease, sponsored by Boehringer Ingelheim. Recruiting at 47 sites in 22 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim — 4 open to participants now, 6 under way, 4 of them phase 3. Lung Diseases, Interstitial · Boehringer Ingelheim.
Among the 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim, this one is the 11th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 11 in phase 3, and was the 23rd registered.
682 studies on the registry are indexed under Lung Diseases, Interstitial; 246 are open to participants now.
Browse Lung Diseases, Interstitial studies →4 of the 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim are open now, in 12 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 17 more countries
Ages 18+
Boehringer Ingelheim · Sites in United States, Argentina, Australia and 10 more countries
Ages 40+
Boehringer Ingelheim · Sites in Mexico
Ages 18+
By country, each count listing its studies:
Of the 173 Lung Diseases, Interstitial studies recruiting now, 108 (62%) set no upper age limit and 25 (14%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 35 is below the median of 60 across 386 interventional studies indexed under Lung Diseases, Interstitial.
Median enrollment 248 across the 12 interventional studies, 506 across the 10 observational. Of the 16 that completed or were terminated, 11 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
1 of the studies in Lung Diseases, Interstitial by Boehringer Ingelheim that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06806592Phase 3Boehringer IngelheimA Study to Test Whether Nerandomilast Helps People With Lung Fibrosis Related to Rheumatic Diseases | 2027-04-15 |
Add it to your calendar (.ics) → With an account.
Among the 24 studies in Lung Diseases, Interstitial by Boehringer Ingelheim, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is open to children and adolescents aged 2 to 17 years with interstitial lung disease (ILD). Nerandomilast has just been approved in some countries to help adults with a lung condition called idiopathic pulmonary fibrosis. The purpose of this study is to understand how nerandomilast is tolerated and handled by the body and whether nerandomilast also helps children and adolescents with ILD.
For participants aged 6 to 17 years when joining, the study has 2 parts. In the first part, participants are put into 1 of 2 groups randomly, which means by chance. One group gets nerandomilast and the other group placebo. Placebo looks like nerandomilast but does not contain any medicine.
Participants are twice as likely to be in the nerandomilast group. They take tablets twice a day for 6 months. After these 6 months, in the second part of this study, they get nerandomilast for at least 2 years regardless of what they got in the first part.
Young participants aged 2 to 5 years when joining get nerandomilast from the start. They receive tablets twice a day for at least 2 and a half years.
Depending on when a person joins, the study lasts between 2 and a half years and up to 5 years. During this time, participants may visit the study site about 18 to 30 times. Study doctors collect blood samples to check participants' health and to find out how their body handles the study medicine. Doctors also check the function of the lungs, body growth, and how participants feel. The study doctors also regularly check participants' health and take note of any changes. For participants aged 6 to 17 years, the results are compared between the groups to see whether nerandomilast treatment helps children and adolescents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with fibrosing ILD at Visit 2, as assessed by the investigator based on any of the following:
Documented evidence of clinical progression over time based on either
Further inclusion criteria apply.
Exclusion Criteria:
Further exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A and Part B: Nerandomilast (open-label)
Drug: Nerandomilast
Part A: Nerandomilast (blinded), Part B: Nerandomilast (open-label)
Drug: Nerandomilast
Part A: Placebo (blinded), Part B: Nerandomilast (open-label)
Drug: Placebo
Nerandomilast
Also known as: JASCAYD®
Placebo
Area under the concentration curve (AUC) T,SS based on sampling at steady state using rich sampling in participants from 6 years to less than 18 years and sparse sampling in participants younger than 6 years
Time frame: At week 2 in Part A and Week 28 in Part B
Occurrence of a treatment-emergent adverse event
Time frame: up to Week 26
Absolute change from baseline in oxygen saturation (SpO2) [%] on room air at rest
Time frame: at Week 26 and Week 52
Absolute change from baseline in height [cm]
Time frame: at Week 26 and Week 52
Absolute change from baseline in pediatric quality of life inventory (PedsQL™)
Health-related quality of life will be assessed in children using the PedsQL™ questionnaire. For younger children who are unable to perform self-assessment, a parent proxy may be required. The score ranges from 0-100, a higher score indicates a better health related quality of life.
Time frame: at Week 26 and Week 52
Occurrence of a treatment-emergent adverse event (Yes/No) over the whole trial
Time frame: up to 5 years
Time to first respiratory-related hospitalisation [days] over the whole trial
Time frame: up to 5 years
Time to first acute interstitial lung disease (ILD) exacerbation or death [days] over the whole trial
Time frame: up to 5 years
Time to death [days] over the whole trial
Time frame: up to 5 years
Acceptability based on number/size of tablets
Acceptability is defined as the overall ability and willingness of the participant to use the medicinal product as intended. Assessment of acceptability will be performed by the participant using the acceptability questionnaire.
Time frame: at Week 2 and Week 26
Acceptability based on the use of the dispenser
Time frame: at Week 2 and Week 26
Absolute change from baseline in FVC [% predicted] (applicable to participants ≥6 years)
Time frame: at Week 26 and Week 52
Absolute change from baseline in 6-min walk distance [m] (applicable to participants ≥6 years)
Time frame: at Week 26 and Week 52
Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com
Started Jul 2026 (actual). Primary completion is estimated for Apr 2029, 33 months after the start.
Of 36 phase 3 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 61. This study's planned 33 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nerandomilast